Drug firm Sun Pharmaceutical Industries today said it has received a tentative approval from US health regulator to market generic donepezil hydrochloride tablets used for treating Alzheimer's disease in the American market.
The tentative approval has been given by United States Food and Drug Administration (US FDA) for its abbreviated new drug application (ANDA) to market donepezil hydrochloride tablets in the strengths of 5 mg and 10 mg, the company said in a statement.
"Annual sale in US for these strengths is approximately $2.5 billion," Sun Pharma added.
Donepezil hydrochloride tablets are generic version of drug major Eisai's Aricept tablets and are used in the treatment of Alzheimer's disease.
Shares of Sun Pharma today closed at Rs 448.75 on the Bombay Stock Exchange (BSE), down 0.14 per cent from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app